Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity

Businesswoman Hands On Crystal Ball On Black Background. Fortune Teller Predicting Future

Related Content

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

Feb 09 2018

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

Nov 29 2017

Indisputable: Humira, Biologics Dominate Pharma Sales In 2017

Apr 05 2018

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path

Sep 28 2017

Samsung Bioepis Builds Its Biosimilars Name In Europe

Aug 28 2017

Related Companies

AbbVie Inc.

Samsung Bioepis Co., Ltd.

Samsung Bioepis Co., Ltd.

Biogen, Inc.

Amgen, Inc.

Boehringer Ingelheim GmbH

Novartis AG

Pfizer Inc.

Bristol Myers Squibb Company

Johnson & Johnson

Celltrion, Inc.

Additional Topics

United States Legal Issues Biosimilars Market Intelligence Strategy Intellectual Property Commercial BioPharmaceutical

More from Legal & IP

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window